Microbiome Therapeutics prepares to launch first microbiome modulator after completing Series B financing
08 Nov 2017 --- MicroBiome Therapeutics, LLC (MBT), a company that applies the science of the gastrointestinal (GI) microbiome to promote health and wellness, has announced the completion of a Series B financing that raised approximately US$1 million. MBT intends to use the proceeds to launch its clinically-tested microbiome modulator product in 2018.
The dietary supplement is specifically designed to balance and optimize the GI tract and promote healthy metabolism by nourishing and nurturing the growth of healthful gut bacteria, MBT notes. New and existing investors include Lagniappe Angels, NO/LA Angel Network, Zehnder Communications and other private investors.
“We appreciate the support of our investors, which will enable the planned launch of our lead microbiome modulator next year,” says Dale Pfost, Acting CEO of MBT. “This product is a scientific formulation of natural ingredients designed to support a balanced GI microbiome and promote metabolic health in an easy-to-use, flavorful drink mix.”
“Our two clinical trials, conducted at the Pennington Biomedical Research Center and reported in peer-reviewed publications, demonstrated its benefits in helping to manage hunger, maintain healthy blood sugar levels and promote regularity,” Pfost adds.
The product is described as an all-natural blend of prebiotics, including fermentable fiber and polyphenol antioxidants in a patent-pending blend intended to help nurture and nourish beneficial microorganisms in the lower gut.
MBT reports that the launch of its microbiome modulator will be supported by a two-year e-commerce and social media campaign conducted in partnership with New Orleans-based advertising agency Zehnder Communications. MBT is also assembling a nationwide network of registered dietitians and certified diabetic educators to support the launch.
“With MicroBiome Therapeutics, we saw a unique opportunity to apply our product launch expertise in support of an exciting, first-in-class product from a leading science-based company,” says Jeremy Hunnewell, CFO and Business Strategist for Zehnder Communications. “We believe our expertise, along with our integrative and analytical approaches, will enable MBT to inform and educate consumers about this exciting new type of health-promoting dietary supplement.”
“Our investment reinforces our commitment to making a difference by playing a part in the microbiome revolution,” states Hunnewell, who will be joining the board of directors of MBT.
